# Huons BioPharma signs $83.4M Hutox supply deal with Haemato Pharm

Huons BioPharma signed a deal potentially worth 97.2 billion won ($83.4 million) with Germany's Haemato Pharm to supply its Hutox botulinum toxin for sale in 29 European countries. The deal includes clinical trials in Europe, with marketing expected to begin in 2025.

- Type: Contract
- Announced: 2021-10-26
- Where: Germany
- Value: $83.4M (97.2B KRW)
- Status: announced
- Products: Hutox botulinum toxin
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Huons BioPharma](https://endata.com/companies/58698.md)
- [Haemato Pharm](https://endata.com/companies/58699.md) (customer)

## Sources

- [koreajoongangdaily.com](https://www.koreajoongangdaily.com/business/huons-biopharma-signs-big-hutox-deal-with-germanys-haemato-pharm/10174133), 2021-10-26: "With the supply deal with Haemato, Huons is set to enter the world’s three largest botulinum toxin markets, the United States, China and Europe."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.